The number is striking for a country that spent decades classifying cannabis as a Schedule I substance with no accepted medical use: a federally funded study in the United States has found that cancer patients who used medical cannabis reported meaningful reductions in opioid consumption alongside improvements in pain, nausea, and sleep. For European clinicians and policymakers watching from across the Atlantic, the significance lies less in the findings themselves — which broadly align with a growing body of patient-reported evidence — and more in who paid for the research.

What the Study Found

The study, reported by Marijuana Moment, examined cancer patients who incorporated medical cannabis into their care. Participants reported reductions in opioid use and improvements across a range of cancer-related symptoms, including pain, nausea, and sleep disturbance. The federal funding source gives the findings an institutional weight that privately funded cannabis research has historically lacked, particularly in the United States, where federal prohibition long made such studies nearly impossible to conduct at scale.

The methodology and full dataset have not been independently reviewed by The Mediterranean Leaf, and the publication did not provide access to the underlying journal article. As with any patient-reported outcome study, confounding variables — including differences in cancer type, treatment stage, and baseline opioid dosage — warrant careful interpretation. That said, the directional consistency of these findings with earlier research from Israel, Canada, and several European institutions gives them a degree of credibility that single-country studies alone cannot claim.

The Opioid Question in European Context

Opioid over-prescription is not exclusively a North American problem. Across southern Europe, including in Malta, palliative and oncology care teams increasingly grapple with the balance between adequate pain control and the longer-term risks associated with high-dose opioid regimens. For patients with advanced cancer, where quality of life often matters more than longevity, that calculus is acute.

Medical cannabis was legalised in Malta in 2018 — a distinct framework from the adult-use Cannabis Harm Reduction Association (CHRA) model introduced under Malta's 2021 cannabis reform — and remains available through a separate medical pathway. In practice, access to medical cannabis for oncology patients in Malta has been limited by prescriber familiarity, product availability, and the requirement for specialist sign-off. A small but growing number of Maltese oncologists have begun incorporating cannabis-based medicines into palliative protocols, though systemic uptake remains cautious.

The question the new US study raises, for Malta as much as for Germany or France, is whether federal-level research endorsement changes the conversation among reluctant prescribers. Evidence alone rarely shifts clinical culture overnight. But evidence produced within the institutional framework that previously suppressed it carries a particular kind of signal.

Harm Reduction Framing Matters Here

It is worth being precise about what this study does and does not show. It does not demonstrate that medical cannabis should replace opioids in cancer care. What it suggests — consistent with earlier research — is that cannabis may function as an adjunct therapy, allowing some patients to manage their pain and symptoms at lower opioid doses. That is a harm reduction proposition: not eliminating a drug, but reducing exposure to its more serious risks.

For Malta's ARUC (Authority on the Responsible Use of Cannabis), which oversees adult-use cannabis rather than the medical pathway, the study's direct regulatory relevance is limited. But the broader harm reduction philosophy underpinning ARUC's framework — that informed, regulated access reduces net harm — finds a clear echo in oncology research that positions cannabis as a tool for better patient outcomes rather than a moral hazard.

European advocates and clinicians would do well to read studies like this not as definitive proof but as one more data point in an accumulating record. That record now includes federally endorsed research from a country whose federal government spent fifty years arguing none of it was worth funding. That shift, quiet as it may seem, is harder to ignore than any single study's p-value.

For a Maltese patient navigating a cancer diagnosis and a conversation with their oncologist about pain management, the practical question remains: will this research make it easier to ask about cannabis as part of their care, and will their doctor know enough to answer? That gap — between evidence and clinical readiness — is where the next piece of work lies, in Malta and across Europe.

Key takeaway: A federally funded US study linking medical cannabis to reduced opioid consumption in cancer patients represents an institutional shift in how such research is sanctioned and conducted. For European clinicians and regulators, the findings reinforce a harm reduction case for cannabis in palliative care that patient advocates have long made — but the distance between research and routine clinical practice remains significant, including in Malta.

Sources:
Marijuana Moment

Featured image: Photo by Tima Miroshnichenko on Pexels

Share this article
The link has been copied!